Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA)
This study is ongoing, but not recruiting participants.
Study NCT00699751   Information provided by Bayer

First Received on June 17, 2008.   Last Updated on April 15, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hormone Refractory Prostate Cancer
Bone Metastases
Additional conditions recognized in this trial
Bone Marrow Diseases
Bone Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Prostatic Neoplasms
More general conditions related to this trial
Bone Diseases
Genital Diseases, Male
Genital Neoplasms, Male
Hematologic Diseases
Musculoskeletal Diseases
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Radium-223 dichloride (BAY88-8223)
Placebo
Additional drug interventions recognized in this trial
Hormones
Succinylcholine
More general drug interventions related to this trial
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuromuscular Agents
Neuromuscular Blocking Agents
Neuromuscular Depolarizing Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Bayer
Algeta ASA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services